Background: In general, it seems that both genetic and environmental factors play important roles in the induction of neural tube defects. Lipomyelomeningocele (LipoMMC) is a rather common type of closed neural tube defect, but only limited studies have investigated the potential risk factors of this anomaly. Therefore, the purpose of this case-control study was to investigate the risk factors involved in LipoMMC formation. Material and Method: Various risk factors were evaluated in 35 children between 1 month and 10 years of age with LipoMMC in a hospital-based case-control study. The 2 control arms consisted of 35 children with myelomeningocele (MMC group) and 35 children with congenital anomalies other than central nervous system problems (control group). All groups were matched for age and visited the same hospital. A structured questionnaire was used for the collection of all data, including the mothers' weight and height during pregnancy, education, reproductive history, previous abortions, and socioeconomic status, as well as the parents' consanguinity and family history of the same anomalies. Results: Univariate analysis of the children with LipoMMC compared to the control group showed that the use of periconceptional folic acid supplementation was significantly lower in the MMC and LipoMMC groups compared to the control group. In addition, comparison of the MMC and control groups revealed statistically significant differences regarding the use of folic acid and maternal obesity. In multivariate analysis, use of folic acid in the periconceptional period and during the first trimester was an independent risk factor for LipoMMC and MMC. Furthermore, maternal obesity was a significantly positive risk factor for MMC. Conclusion: The probable risk factors for LipoMMC were investigated in this case-control study. Consumption of folic acid in the periconceptional period and during the first trimester is an independent protective factor against LipoMMC. It seems that larger studies are needed to examine other possible risk factors.

Keywords:
Lipomyelomeningocele, Risk factors, Folic acid
1.
Li L, Wang J, Wu J: A spatial model to predict the incidence of neural tube defects. BMC Public Health 2012;12:951.
2.
Tortori-Donati P, Rossi A, Cama A: Spinal dysraphism: a review of neuroradiological features with embryological correlations and proposal for a new classification. Neuroradiology 2000;42:471-491.
3.
Arai H, Sato K, Okuda O, Miyajima M, Hishii M, Nakanishi H, Ishii H: Surgical experience of 120 patients with lumbosacral lipomas. Acta Neurochir (Wien) 2001;143:857-864.
4.
Guggisberg D, Hadj-Rabia S, Viney C, Bodemer C, Brunelle F, Zerah M, Pierre-Kahn A, de-Prost Y, Hamel-Teillac D: Skin markers of occult spinal dysraphism in children: a review of 54 cases. Arch Dermatol 2004;140:1109-1115.
5.
Gibson PJ, Britton J, Hall DM, Hill CR: Lumbosacral skin markers and identification of occult spinal dysraphism in neonates. Acta Paediatr 1995;84:208-209.
6.
Warder DE: Tethered cord syndrome and occult spinal dysraphism. Neurosurg Focus 2001;10:e1.
7.
Agopian AJ, Canfield MA, Olney RS, Lupo PJ, Ramadhani T, Mitchell LE, Shaw GM, Moore CA: Spina bifida subtypes and sub-phenotypes by maternal race/ethnicity in the National Birth Defects Prevention Study. Am J Med Genet A 2012;158:109-115.
8.
De-Wals P, Van-Allen MI, Lowry RB, Evans JA, Vanden-Hof MC, Crowley M, Tairou F, Uh SH, Sibbald B, Zimmer P, Fernandez B, Lee NS, Niyonsenga T: Impact of folic acid food fortification on the birth prevalence of lipomyelomeningocele in Canada. Birth Defects Res A Clin Mol Teratol 2008;82:106-109.
9.
McAtee-Smith J, Hebert AA, Rapini RP, Goldberg NS: Skin lesions of the spinal axis and spinal dysraphism: fifteen cases and a review of the literature. Arch Pediatr Adolesc Med 1994;148:740-748.
10.
McNeely PD, Howes WJ: Ineffectiveness of dietary folic acid supplementation on the incidence of lipomyelomeningocele: pathogenetic implications. J Neurosurg 2004;100:98-100.
11.
Carter CO, Evans KA, Till K: Spinal dysraphism: genetic relation to neural tube malformations. J Med Genet 1976;13:343-350.
12.
Williams LJ, Mai CT, Edmonds LD, Shaw GM, Kirby RS, Hobbs CA, Sever LE, Miller LA, Meaney FJ, Levitt M: Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 2002;66:33-39.
13.
Forrester MB, Merz RD: Descriptive epidemiology of lipomyelomeningocele, Hawaii, 1986-2001. Birth Defects Res A Clin Mol Teratol 2004;70:953-956.
14.
Shaw GM, Todoroff K, Finnell RH, Lammer EJ: Spina bifida phenotypes in infants or fetuses of obese mothers. Teratology 2000;61:376-381.
15.
Stothard KJ, Tennant PW, Bell R, Rankin J: Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 2009;301:636-650.
16.
Lindhout D, Omtzigt JG, Cornel M: Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42:111-118.
17.
Hendricks KA, Nuno OM, Suarez L, Larsen R: Effects of hyperinsulinemia and obesity on risk of neural tube defects among Mexican Americans. Epidemiology 2001;12:630-635.
18.
Yazdy MM, Liu S, Mitchell AA, Werler MM: Maternal dietary glycemic intake and the risk of neural tube defects. Am J Epidemiol 2010;171:407-414.
19.
Ceyhan ST, Beyan C, Atay V, Yaman H, Alanbay I, Kaptan K, Baser I: Serum vitamin B12 and homocysteine levels in pregnant women with neural tube defect. Gynecol Endocrinol 2010;26:578-581.
20.
Muthukumar N: Congenital spinal lipomatous malformations. 1. Classification. Acta Neurochir (Wien) 2009;151:179-188, discussion 197.
21.
Beaudin AE, Stover PJ: Insights into metabolic mechanisms underlying folate-responsive neural tube defects: a minireview. Birth Defects Res A Clin Mol Teratol 2009;85:274-284.
22.
Waller DK, Shaw GM, Rasmussen SA, Hobbs CA, Canfield MA, Siega-Riz AM, Gallaway MS, Correa A: Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 2007;161:745-750.
23.
Moretti ME, Bar-Oz B, Fried S, Koren G: Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology 2005;16:216-219.
24.
Grewal J, Carmichael SL, Song J, Shaw GM: Neural tube defects: an analysis of neighbourhood- and individual-level socio-economic characteristics. Paediatr Perinat Epidemiol 2009;23:116-124.
25.
Canfield MA, Ramadhani TA, Shaw GM, Carmichael SL, Waller DK, Mosley BS, Royle MH, Olney RS: Anencephaly and spina bifida among Hispanics: maternal, sociodemographic, and acculturation factors in the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2009;85:637-646.
26.
Brough L, Rees GA, Crawford MA, Dorman EK: Social and ethnic differences in folic acid use preconception and during early pregnancy in the UK: effect on maternal folate status. J Hum Nutr Diet 2009;22:100-107.
27.
Matok I, Gorodischer R, Koren G, Landau D, Wiznitzer A, Levy A: Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. Br J Clin Pharmacol 2009;68:956-962.
28.
Sebold CD, Melvin EC, Siegel D, Mehltretter L, Enterline DS, Nye JS, Kessler J, Bassuk A, Speer MC, George TM: Recurrence risks for neural tube defects in siblings of patients with lipomyelomeningocele. Genet Med 2005;7:64-67.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.